Bio-Rad Laboratories has been assigned a 'Buy' rating due to the involvement of activist investor Elliott, which is expected to drive further operational improvements. The company is shifting its acquisition strategy towards revenue-generating bolt-ons and rationalizing its R&D spending. Additionally, the potential sale of Bio-Rad's Sartorius stake, valued at over $5 billion, is seen as more likely with Elliott's involvement, given Elliott is also a Sartorius shareholder. These changes suggest significant re-rating potential for Bio-Rad going forward.

More News (BIO)

Oxidative Stress Assay Market to hit $3.25B by 2035, driven by chronic disease and pharma R&D growth

The global Oxidative Stress Assay Market, valued at $1.31 billion in 2025, is projected to reach $3.25 billion by 2035, growing at a CAGR of 9.53%. Growth is fueled by rising chronic diseases, pharmaceutical innovation, and advances in biomarker diag...

Market News

Bullish

3 days ago

Bio-Rad Laboratories rated 'Buy' as activist Elliott prompts operational improvements and potential $5B Sartorius stake sale.

More News (BIO)

Oxidative Stress Assay Market to hit $3.25B by 2035, driven by chronic disease and pharma R&D growth

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Bio-Rad Laboratories rated 'Buy' as activist Elliott prompts operational improvements and potential $5B Sartorius stake sale.

More News (BIO)

Oxidative Stress Assay Market to hit $3.25B by 2035, driven by chronic disease and pharma R&D growth

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App